Tags

Type your tag names separated by a space and hit enter

A candidate multi-epitope vaccine against SARS-CoV-2.
Sci Rep. 2020 07 02; 10(1):10895.SR

Abstract

In the past two decades, 7 coronaviruses have infected the human population, with two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively. Currently, the entire world is facing a pandemic of another coronavirus, SARS-CoV-2, with a high fatality rate. The spike glycoprotein of SARS-CoV-2 mediates entry of virus into the host cell and is one of the most important antigenic determinants, making it a potential candidate for a vaccine. In this study, we have computationally designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2. The overall quality of the candidate vaccine was validated in silico and Molecular Dynamics Simulation confirmed the stability of the designed vaccine. Docking studies revealed stable interactions of the vaccine with Toll-Like Receptors and MHC Receptors. The in silico cloning and codon optimization supported the proficient expression of the designed vaccine in E. coli expression system. The efficiency of the candidate vaccine to trigger an effective immune response was assessed by an in silico immune simulation. The computational analyses suggest that the designed multi-epitope vaccine is structurally stable which can induce specific immune responses and thus, can be a potential vaccine candidate against SARS-CoV-2.

Authors+Show Affiliations

Department of Life Sciences, Garden City University, Bangalore, Karnataka, India.Department of Life Sciences, Garden City University, Bangalore, Karnataka, India.Department of Life Sciences, Garden City University, Bangalore, Karnataka, India.Department of Life Sciences, Garden City University, Bangalore, Karnataka, India.Institute for Applied Computing, National Research Council of Italy, Via dei Taurini, Rome, Italy.Center for Genetic Diseases, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, USA.Department of Life Sciences, Garden City University, Bangalore, Karnataka, India. anurag.srivastava@gardencity.university.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32616763

Citation

Kar, Tamalika, et al. "A Candidate Multi-epitope Vaccine Against SARS-CoV-2." Scientific Reports, vol. 10, no. 1, 2020, p. 10895.
Kar T, Narsaria U, Basak S, et al. A candidate multi-epitope vaccine against SARS-CoV-2. Sci Rep. 2020;10(1):10895.
Kar, T., Narsaria, U., Basak, S., Deb, D., Castiglione, F., Mueller, D. M., & Srivastava, A. P. (2020). A candidate multi-epitope vaccine against SARS-CoV-2. Scientific Reports, 10(1), 10895. https://doi.org/10.1038/s41598-020-67749-1
Kar T, et al. A Candidate Multi-epitope Vaccine Against SARS-CoV-2. Sci Rep. 2020 07 2;10(1):10895. PubMed PMID: 32616763.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A candidate multi-epitope vaccine against SARS-CoV-2. AU - Kar,Tamalika, AU - Narsaria,Utkarsh, AU - Basak,Srijita, AU - Deb,Debashrito, AU - Castiglione,Filippo, AU - Mueller,David M, AU - Srivastava,Anurag P, Y1 - 2020/07/02/ PY - 2020/04/16/received PY - 2020/06/12/accepted PY - 2020/7/4/entrez PY - 2020/7/4/pubmed PY - 2020/7/16/medline SP - 10895 EP - 10895 JF - Scientific reports JO - Sci Rep VL - 10 IS - 1 N2 - In the past two decades, 7 coronaviruses have infected the human population, with two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively. Currently, the entire world is facing a pandemic of another coronavirus, SARS-CoV-2, with a high fatality rate. The spike glycoprotein of SARS-CoV-2 mediates entry of virus into the host cell and is one of the most important antigenic determinants, making it a potential candidate for a vaccine. In this study, we have computationally designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2. The overall quality of the candidate vaccine was validated in silico and Molecular Dynamics Simulation confirmed the stability of the designed vaccine. Docking studies revealed stable interactions of the vaccine with Toll-Like Receptors and MHC Receptors. The in silico cloning and codon optimization supported the proficient expression of the designed vaccine in E. coli expression system. The efficiency of the candidate vaccine to trigger an effective immune response was assessed by an in silico immune simulation. The computational analyses suggest that the designed multi-epitope vaccine is structurally stable which can induce specific immune responses and thus, can be a potential vaccine candidate against SARS-CoV-2. SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/32616763/A_candidate_multi_epitope_vaccine_against_SARS_CoV_2_ L2 - https://doi.org/10.1038/s41598-020-67749-1 DB - PRIME DP - Unbound Medicine ER -